Clinical Trial Update: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination in treatment-naive and treatment-experienced subjects with chro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genotype 4 Hcv
• Genotype 5 Hcv

Drugs mentioned

• Ledipasvir/Sofosbuvir fixed-dose combination (Ledipasvir + Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Genotype 4 HCV, Chronic Genotype 5 HCV | Phase 2 | Status: COMPLETED | Results posted: 2016-01-14